Dasatinib and Quercetin (D+Q): The Senolytic Combo Explained
Dasatinib and Quercetin (D+Q): The Senolytic Combo Explained
The short answer: Dasatinib plus quercetin, usually written D+Q, is the original senolytic combination. It pairs a prescription leukemia drug with a plant flavonoid to selectively kill senescent “zombie” cells. In old mice the combo improves physical function and extends remaining lifespan. In humans the evidence is limited to small, mostly open-label pilot trials. Dasatinib is a serious prescription drug, so this is not a supplement to self-experiment with casually.
Key Takeaways
- What it is: A two-drug senolytic combo. Dasatinib is an FDA-approved tyrosine kinase inhibitor (brand name Sprycel) used for leukemia. Quercetin is a flavonoid found in onions, apples, and capers and sold as a supplement.
- How it works: Senescent cells survive by switching on anti-apoptotic defenses. D+Q briefly disables those defenses, tipping the senescent cells into self-destruction. They target different cell types, so the pair covers more ground than either alone [1].
- What the trials show: Strong mouse data for better physical function and longer lifespan [2]. In humans, small pilots show senescent cells can be cleared [4] and physical function improved in one lung-disease study [3], but no large controlled trial has proven benefit.
- Dosing style: Intermittent “hit-and-run” dosing, typically a few consecutive days every few weeks, rather than daily use.
- Evidence grade: Early. Compelling mechanism and animal data, thin and preliminary human data. Dasatinib carries real prescription-drug risks.
What are dasatinib and quercetin?
The two halves of D+Q come from very different places. Dasatinib is a tyrosine kinase inhibitor approved by the FDA in 2006, sold as Sprycel, to treat chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia. It is a potent prescription cancer drug, not a supplement. Quercetin is a flavonol found in everyday foods such as onions, apples, berries, and capers, and it is widely available over the counter as a dietary supplement.
On their own, neither was designed to fight aging. They were paired after a deliberate search for compounds that could kill senescent cells, which is how the entire senolytic field began [1].
How does D+Q work in the body?
As cells age or take on damage, some enter a state called senescence. They stop dividing but refuse to die, and they leak a mix of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. These “zombie” cells accumulate with age and are thought to drive chronic inflammation and tissue decline.
Senescent cells survive because they lean heavily on anti-apoptotic defense networks, sometimes called SCAPs (senescent cell anti-apoptotic pathways). In 2015, researchers reasoned that briefly blocking those networks should push senescent cells over the edge into apoptosis, their built-in self-destruct program. Screening identified dasatinib and quercetin as the first drugs that did this [1]. Dasatinib is better at clearing senescent fat-cell progenitors, while quercetin is more effective against senescent endothelial cells, so combining them broadens the range of cell types cleared.
Because senolytics only need to knock out the survival signal long enough to trigger apoptosis, they are given in short, intermittent courses rather than continuously. This “hit-and-run” approach is a defining feature of the class and sets senolytics apart from anti-inflammatory “senomorphic” drugs that must be taken constantly.
What does the animal evidence show?
The mouse data are the strongest part of the D+Q story. A landmark 2018 study in Nature Medicine showed that senolytics, including D+Q, improved physical function in aged mice and, remarkably, extended their remaining lifespan even when treatment started late in life [2]. Transplanting a small number of senescent cells into young mice was enough to cause physical dysfunction, and clearing those cells with senolytics reversed it. These findings are what pushed D+Q toward human testing.
What do the human trials show?
Human evidence exists, but it is early and should be read with caution. The published trials are small, mostly open-label, and short.
The first-in-human study, published in EBioMedicine in 2019, treated 14 patients with idiopathic pulmonary fibrosis, a serious scarring lung disease linked to cellular senescence. Over three weeks of intermittent D+Q, patients showed improvements in physical-function measures such as walking distance, gait speed, and repeated chair stands. Lung function itself did not change, and there was no placebo group [3].
A second 2019 EBioMedicine report studied nine people with diabetic kidney disease. After just three days of D+Q, biopsies showed a measurable drop in senescent-cell burden in fat and skin tissue, along with lower levels of several circulating SASP factors. This was the first direct human proof that senolytics actually clear senescent cells in people, rather than only in mice [4].
More recently, the SToMP-AD phase 1 feasibility trial, published in Nature Medicine in 2023, gave D+Q to patients with mild Alzheimer’s disease. It was designed to test safety and whether the drugs reach the brain, not to prove benefit. The combo was tolerated and showed evidence of central-nervous-system penetration, setting up larger studies [5].
| Trial (year) | Population | Design | Main finding |
|---|---|---|---|
| Xu et al., Nature Medicine (2018) | Aged mice | Preclinical | Improved physical function and extended remaining lifespan [2] |
| Hickson et al., EBioMedicine (2019) | 14 adults with IPF | Open-label pilot | Better walking distance, gait speed, chair stands; no lung-function change [3] |
| Justice et al., EBioMedicine (2019) | 9 adults with diabetic kidney disease | Open-label pilot | Reduced senescent cells in fat and skin; lower SASP markers [4] |
| Gonzales et al., Nature Medicine (2023) | Adults with mild Alzheimer’s | Phase 1 feasibility | Tolerated; evidence the drugs reached the brain [5] |
What dose was used, and is it safe?
The human pilots used intermittent dosing rather than daily supplements. A representative schedule was dasatinib 100 mg per day plus quercetin 1,000 to 1,250 mg per day for three consecutive days, repeated after a break of days to weeks [3][4]. The logic is that senolytics only need to be present long enough to trigger apoptosis in senescent cells.
Safety is the part that deserves the most emphasis. Dasatinib is a prescription cancer drug with well-documented risks, including fluid retention and pleural effusion, low blood-cell counts, increased bleeding risk, and heart-rhythm effects. It is not a benign compound. Quercetin is generally well tolerated but can inhibit drug-metabolizing enzymes and interact with medications. The published human trials were short and small, so long-term safety of D+Q as an anti-aging regimen in otherwise healthy people has not been established. Buying dasatinib from gray-market sources to self-dose is genuinely risky and not supported by the evidence.
What has not been shown yet?
The honest summary is that D+Q is a promising idea with real but preliminary human data. What has been shown is that senolytics can reduce senescent-cell burden in humans [4] and that D+Q improved physical function in one small lung-disease study [3]. What has not been shown is that D+Q extends human lifespan, prevents age-related disease, or delivers meaningful anti-aging benefits in healthy adults. Those claims rest on mouse studies and mechanism, not on completed, controlled human trials. Larger randomized trials are underway, and their results will decide whether the mouse promise carries over to people.
Frequently asked questions
Is dasatinib available over the counter?
No. Dasatinib is a prescription-only tyrosine kinase inhibitor approved to treat certain leukemias. It is a potent drug with serious potential side effects and is not sold as a supplement. Quercetin, the other half of the combo, is available over the counter, but the dasatinib component requires a prescription and medical supervision.
How is D+Q dosed?
In the human pilot trials, D+Q was given intermittently rather than daily, for example dasatinib 100 mg plus quercetin 1,000 to 1,250 mg for three consecutive days, then a gap of days to weeks before repeating. This “hit-and-run” schedule reflects how senolytics work: they only need to be present briefly to push senescent cells into self-destruction.
Does D+Q actually clear senescent cells in humans?
Preliminary evidence says yes. In a 2019 pilot in people with diabetic kidney disease, three days of D+Q measurably reduced senescent-cell markers in fat and skin biopsies and lowered several inflammatory SASP factors in the blood. That was the first direct human proof that senolytics clear senescent cells, though it was a small, open-label study [4].
Who should not take D+Q?
D+Q should only be considered under medical supervision, and many people should avoid it entirely. That includes anyone who is pregnant or breastfeeding, people under 18, and anyone on medications that interact with dasatinib or quercetin or that carry bleeding or heart-rhythm risks. Because dasatinib is a serious prescription drug, self-experimentation outside a clinical setting is not advisable [3].
Bottom Line
Evidence grade: Early. Dasatinib plus quercetin is the founding senolytic combination and has the most complete story in the field: a clear mechanism, strong mouse data showing better function and longer life, and the first human proof that senescent cells can be cleared. But the human trials so far are small, short, and mostly open-label, and no completed controlled study proves anti-aging benefit in healthy people. Just as important, dasatinib is a prescription cancer drug with real risks, which makes casual self-dosing a poor idea. D+Q is one of the most scientifically interesting interventions in longevity research and, at the same time, one to approach with patience and medical oversight rather than enthusiasm alone.
This article is for educational purposes only and is not medical advice. Dasatinib is a prescription drug with serious potential side effects, and both compounds can interact with medications and health conditions. Talk with a qualified healthcare professional before considering dasatinib, quercetin, or any senolytic protocol, especially if you are pregnant, breastfeeding, taking prescription medication, or managing a chronic condition.
References
- Zhu Y, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. PMID 25754370
- Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID 29988130
- Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. PMID 30616998
- Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019. PMID 31542391
- Gonzales MM, et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nature Medicine. 2023. PMID 37679434
